AFNAS
OREX

American Financial Network Advisory Services’s Orexigen Therapeutics, Inc. OREX Stock Holding History

American Financial Network Advisory Services’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-100
Closed – – 822
2017
Q3 		$0 Buy
+100
New +$244 ﹤0.01% 782

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

American Financial Network Advisory Services's OREX Position: Q4 2017 in Review

American Financial Network Advisory Services sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 100 shares.

American Financial Network Advisory Services first reported a position in OREX in Q3 2017 and held it in 1 quarter. The position peaked at $0 in Q3 2017. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

  • American Financial Network Advisory Services reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • American Financial Network Advisory Services sold 100 Orexigen Therapeutics, Inc. shares in Q4 2017.
  • American Financial Network Advisory Services first reported a position in Orexigen Therapeutics, Inc. in Q3 2017 and held it in 1 quarter.
  • American Financial Network Advisory Services's Orexigen Therapeutics, Inc. position peaked at $0 in Q3 2017.
  • 41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on American Financial Network Advisory Services's 13F filing for Q4 2017, filed 2 Jan 2018.